Credent and CardioTech strike technology deal:
This article was originally published in Clinica
Executive Summary
Medical device company Credent has struck a $500,000 technology transfer and licensing deal with Woburn, Massachusetts-based CardioTech International. The exclusive deal, which enables Credent to synthesise Chronoflex RC biodurable polycarbonate-urethane, also involves CardioTech retaining certain rights to Chronoflex RC for the manufacture and marketing of coronary artery bypass grafts. Credent, based in Wrexham, Wales, will use the technology in its current vascular access and peripheral vascular grafts range and in new products.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.